4. Phase 1a: histological or cytological confirmation of a solid, malignant tumor (excluding CNS tumors), that is refractory to standard therapies or for which no standard therapies exist. Phase 1b: histological or cytological confirmation of NSCLC with prior anti-PD-1 therapy.